Local cytokines and clinical symptoms in children with allergic rhinitis after different treatments

Biologics: Targets and Therapy

Volumn 3, Issue , 2009, Pages 469-474

  Segundo, Gesmar R S ^a   Gomes, Fabíola A ^a   Fernandes, Karla P ^a   Alves, Ronaldo ^a   Silva, Deise A O ^a   Taketomi, Ernesto A ^a  

^a FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

Author keywords

Allergic rhinitis; Allergy; Cytokines; Desloratadine; IFN ; IL 5; Mometasone; Montelukast; Nasal fluid

Indexed keywords

EID: 78650871689     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S7011     Document Type: Article

References (30)

1. Bousquet J, Van Cauwenberge P, Khaltaev N; Aria Workshop Group. World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108:S147-S334.
2. Settipane RJ, Hagy GW, Settipane GA. Long-term risk factors for developing asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Proc. 1994;15:21-25.
3. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol. 2001;108:S2-S8.
4. Solé D, Wandalsen GF, Camelo-Nunes IC, Naspitz CK; ISAAC-Brazilian Group. Prevalence of symptoms of asthma, rhinitis, and atopic eczema among Brazilian children and adolescents identified by International Study of Asthma and Allergies in Childhood (ISSAC)-Fase 3. J Pediatr (Rio J). 2006;82:341-346.
5. Meltzer EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol. 2001;108:S45-S53.
6. Fineman SM. The burden of allergic rhinitis: beyond dollars and cents. Ann Allergy Asthma Immunol. 2002;88:S2-S7.
7. Schoenwetter WF, Dupclay L Jr, Appajosyula S, Botteman MF, Pashos CL. Economic impact and quality-of-life burden of allergic rhinitis. Curr Med Res Opin. 2004;20:305-317.
8. Platts-Mills TA, Vaughan JW, Carter MC, Woodfolk JA. The role of intervention in established allergy: avoidance of indoor allergens in the treatment of chronic allergic disease. J Allergy Clin Immunol. 2000;106:787-804.
9. Bousquet J, Cauwenberge P, Khaled NA, et al. Pharmacologic and anti-IgE of allergic rhinitis ARIA update (in collaboration with GA2LEN). Allergy. 2006;61:1086-1096.
10. Ownby D. Allergy testing: in vivo versus in vitro. Pediatr Clin North Am. 1988;3:995-1009.
11. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8-160.
12. Peters-Golden M, Henderson JR. The role of leukotrienes in allergic rhinitis. Ann Allergy Asthma Immunol. 2005;94:609-618.
13. Oliveira CA, Braga CR, Sole D, Naspitz CK. Intranasal azelastine in the treatment of perennial allergic rhinitis in children. J Pediatr (Rio J). 1996;72:394-399.
14. Tworek D, Bochenska-Marciniak M, Kupczyk M, Gorski P, Kuna P. The effect of 4 weeks treatment with desloratadine (5 mg daily) on levels of interleukin (IL)-4, IL-10, IL-18 and TGF beta in patients suffering from seasonal allergic rhinitis. Pulm Pharmacol Ther. 2007;20: 244-249.
15. Ciebiada M, Gorska-Ciebiada M, DuBuske LM, Gorski P. Montelukast with desloratadine or levocetirizine for the treatment of persistent allergic rhinitis. Ann Allergy Asthma Immunol. 2006;97:664-671.
16. Virchow JC, Bachert C. Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. Respir Med. 2006;100:1952-1959.
17. Kovalhuk LC, Rosario NA, Carvalho A. Inflammatory mediators, cell counts in nasal lavage and computed tomography of the paranasal sinuses in atopic children. J Pediatr (Rio J). 2001;77:271-278.
18. Rizzo MC, Sole D. Inhaled corticosteroids in the treatment of respiratory allergy: safety vs efficacy. J Pediatr (Rio J). 2006;82:S198-S205.
19. Zitt M, Kosoglou T, Hubbell J. Mometasona furoate nasal spray: a review of safety and systemic effects. Drugs Saf. 2007;30:317-326.
20. Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy. 2008;63:1292-1300.
21. Valero A, Alonso J, Antepara I, et al. Development and validation of a new Spanish instrument to measure health-related quality of life in patients with allergic rhinitis: the ESPRINT questionnaire. Value Health. 2007;10:466-477.
22. Passalacqua G, Canonica GW, Baiardini I. Rhinitis, rhinosinusitis and quality of life in children. Pediatr Allergy Immunol. 2007;18(Suppl 18):40-45.
23. Ciprandi G, Tosca MA, Cirillo I, Vizzaccaro A. The effect of budesonide on the cytokine pattern in patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2003;91:467-471.
24. Erin EM, Leaker BR, Zacharasiewicz AS, et al. Single dose topical corticosteroid inhibits IL-5 and IL-13 in nasal lavage following grass pollen challenge. Allergy. 2005;60:1524-1529.
25. Erin EM, Zacharasiewicz AS, Nicholson GC, et al. Topical corticosteroid inhibits interleukin-4,-5 and-13 in nasal secretions following allergen challenge. Clin Exp Allergy. 2005;35:1608-1614.
26. Bradding P, Feather IH, Wilson S, Holgate ST, Howarth PH. Cytokine immunoreactivity in seasonal rhinitis: regulation by a topical corticosteroid. Am J Respir Crit Care Med. 1995;151:1900-1906.
27. Parameswaran K, Fanat A, Byrne PM. Effects of intranasal fluticasone and salmeterol on allergen-induced nasal responses. Allergy. 2006;61:731-736.
28. Ciprandi G, Frati F, Marcucci F, et al. Nasal cytokine modulation by montelukast in allergic children: a pilot study. Allerg Immunol (Paris). 2003;35:295-299.
29. Ciprandi G, Cirillo I, Vizzaccaro A, et al. Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: A pilot study. Int Immunopharmacol. 2005;5:1800-1808.
30. Saengpanich S, Assanasen P, deTineo M, Haney L, Naclerio RM, Baroody FM. Effects of intranasal azelastine on the response to nasal allergen challenge. Laryngoscope. 2002;112:47-52.